世界の消化器疾患治療薬市場：タイプ、投与経路、用途、地域別（2018年〜2023年）

世界の消化器疾患治療薬市場は、2018年から2023年の調査期間を通じて5.8%のCAGRで推移することが予測されています。

当レポートでは、世界の消化器疾患治療薬市場を調査し、市場の概要、タイプ・投与経路・治療領域・地域別の市場規模の推移と予測、市場動向、市場の成長要因および阻害要因の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

• 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

• 現在の市場シナリオ
• ファイブフォース分析
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係

第6章 市場のダイナミクス

• 成長要因
  • ライフスタイルの変化による消化器疾患および癌の増加
  • 消化器疾患の手術件数の増加
  • 製薬企業による生物学的製剤およびバイオシミラーへの投資増加
• 阻害要因
  • 消化器疾患に付随する社会経済的負担の増大
  • 特許満了を迎えた医薬品の増加
• 市場機会
• 主な課題

第7章 市場セグメンテーション

• タイプ別
  • 先発医薬品
  • 後発医薬品（ジェネリック医薬品）
• 投与経路別
  • 経口投与
  • 非経口投与
  • その他
• 用途別
  • 潰瘍性大腸炎
  • 過敏性腸症候群
  • クローン病
  • セリアック病
  • 胃腸炎
  • 胃癌
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • 南米

第8章 競合情勢

• M&A分析
• 合意、コラボレーション、パートナーシップ
• 新製品の発売

第9章 主要企業

• Abbott
• Allergan PLC
• アステラス製薬
• AstraZeneca
• Bayer AG
• GlaxoSmithKline PLC
• Janssen Pharmaceuticals, Inc.
• Pfizer Inc.
• Salix Pharmaceuticals
• 武田薬品工業

第10章 市場の将来展望

Market Overview

The gastrointestinal therapeutics market is majorly driven by lifestyle changes leading to GI diseases. According to the National Health Interview Survey, 2017, 15.3 million adults were diagnosed with ulcers in the US. Other driving factors include rising surgical treatments and hospitalizations due to GI diseases and increasing R&D investments by biopharmaceutical companies in developing biologics and biosimilars. However, an increasing number of patent expirations and other factors such as physiological, behavioral, psychosocial, and socio-environmental risk factors, also restrict the populations from reporting the diseases early which reflects low awareness as well as an economic burden, restring the growth of the gastrointestinal therapeutics market.

Scope of the Report

Gastrointestinal disorders are the term used to refer to any condition or disease that occurs within the gastrointestinal tract. The gastrointestinal tract (also called the GI tract) is a series of hollow organs that form a long continuous passage from our mouth to our anus. The organs that make up our GI tract are our mouth, esophagus, stomach, small intestine, large intestine, and anus. Gastrointestinal (GI) complaints are common among infants, children, and adults, which results from the reflux of stomach contents into the esophagus. The upper GI tract has shown highly prevalent disorders in specialized and primary cares. It constitutes a large proportion of outpatients and frequent hospital visits globally.

Key Market Trends

Inflammatory ulcerative colitis holds significant market share

The inflammatory ulcerative colitis disease is often a relapsing and remitting disease. The disease often deals with lifelong treatment therapies. However, the current treatment options have several adverse effects, poor efficacy profiles, and sometimes, the cost of the drug is highly expensive, which makes this segment lucrative for the biopharmaceutical companies. Some of the traditional classes of drugs are helpful for inflammatory bowel disease (IBD) including 5-aminosalicylic acid, corticosteroids, and immune-modulating drugs. Biologic drugs have also been explored in the past two decades, with several being marketed, which include anti-TNF drugs, immunosuppressive interleukins, and anti-interleukin antibodies. As per Merck & Co. Inc., 2018, apart from the presence of diverse medication facilities, still one-third of the overall patient population suffering from UC ultimately require surgery. Takeda Pharmaceuticals, Jassen Pharmaceuticals, Pfizer are among the major global companies that have established themselves well in the treatment of inflammatory ulcerative colitis.

The Asia Pacific is the fastest growing region in the Global Gastrointestinal Therapeutics Market

The Asian countries have shown the similar trend of growth in recent years as compared to western developed markets particularly owing to increasing economic growth along with privatization, competitive site experience, technological expertise, infrastructure, and scale to manage large-scale clinical trials across India, China, Japan, South Korea, and others. The stomach related diseases have shown similar growth characteristics (incidence and prevalence) to western countries and thus the data of clinical trials are routinely accepted as part of US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory authorities. The unmet medical need and potential market opportunity have accelerated the partnerships with Asian pharmaceutical companies for development and commercial potential in the growth of the pharmaceutical business.

Competitive Landscape

There is a rising trend towards the development of targeted therapeutics products by the companies. In the process of finding innovative methods, the companies are majorly expanding their pipeline and product portfolio through collaborations with specialized companies in the gastrointestinal therapeutics and devices. For instance, In July 2018: HiFiBiO Therapeutics collaborated with Takeda, in a multi-target agreement for the discovery of breakthrough antibody therapies to potentially treat a variety of gastrointestinal diseases, cancers, and other disorders. The major players in the market include Abbott, Allergan, GlaxoSmithKline PLC, Pfizer, Takeda Pharmaceutical Company Limited, among others.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• Report customization as per the client's requirements
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence of GI Diseases
  • 4.2.2 Increasing Investments in R&D by Pharmaceutical Companies
• 4.3 Market Restraints
  • 4.3.1 Rising Socio-Economic Burden Associated with Gastrointestinal Disorders
  • 4.3.2 Increasing Number of Patent Expirations
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 Drug Type
  • 5.1.1 Antacids
  • 5.1.2 laxatives
  • 5.1.3 Antidiarrheal agents
  • 5.1.4 Antiemetics
  • 5.1.5 Antiulcer agents
  • 5.1.6 Others
• 5.2 Dosage Form
  • 5.2.1 Oral
  • 5.2.2 Parenteral
  • 5.2.3 Others
• 5.3 Application
  • 5.3.1 Inflammatory Ulcerative Colitis
  • 5.3.2 Irritable Bowel Syndrome
  • 5.3.3 Crohn's Disease
  • 5.3.4 Celiac Disease
  • 5.3.5 Gastroenteritis
  • 5.3.6 Others
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 US
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 UK
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Abbott Laboratories
  • 6.1.2 Allergan PLC
  • 6.1.3 Astellas Pharma Inc.
  • 6.1.4 AstraZeneca
  • 6.1.5 Bayer AG
  • 6.1.6 GlaxoSmithKline PLC
  • 6.1.7 Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
  • 6.1.8 Pfizer Inc.
  • 6.1.9 AbbVie, Inc.
  • 6.1.10 Takeda Pharmaceutical Company Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS